Member LoginDividend CushionValue Trap
|
Valuentum
Reports
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Latest
Valuentum Commentary
Nov 16, 2016
Pharma, Biotech and How to Consider Investing In It
The Valuentum analyst team digs deep into recent trends in big pharma and biotech from the lofty pricing of drugs to political and competitive pressures to ETF considerations and beyond. ~10 mins. Nov 10, 2016
Assessing Reactions to Trump’s Victory
Image Source: Gage Skidmore. Donald Trump will be the 45th President of the United States of America. Let’s dig into some of the reactions across the market. We’re keeping our cool. Nov 2, 2016
Earnings Insight – Gilead Sciences
Image Source: Gilead. Let’s cover some ground on Gilead Sciences third-quarter report. Oct 21, 2016
Pharma Momentum Builds for Johnson & Johnson
Image Source: J&J. Dividend growth giant Johnson & Johnson reported impressive results in the third quarter of 2016 as momentum in its business continues to build. Oct 14, 2016
Where I Went Wrong on Gilead
Image Source: torbakhopper. Let’s walk through our run-in with Gilead. Sep 15, 2016
Getting the Job Done
A sneak peak at the introduction to the September edition of the Best Ideas Newsletter. Sep 12, 2016
The Quiet Analyst Speaks
Image: Mailslot for Cantor Fitzgerald, on the top floors of the WTC. The mailslot was located in a post office near the WTC site. The mailslots are with the Smithsonian Institution. Travis Wise. Let's get caught up... Aug 10, 2016
Oncology News a Key Driver of Big Pharma
Image Source: Images Money. Oncology product portfolios and pipelines have been key factors in the big pharma industry as of late. Jul 27, 2016
Gilead’s Harvoni Sales Dip Considerably in the US
Image Source: Gilead. The bull case for owning Gilead has become bleak. Jul 19, 2016
The J&J-Gilead Trade-off Update
Some of our members were not happy when we swapped out Gilead and replaced it with Johnson & Johnson in the portfolio of the Best Ideas Newsletter. How have things progressed since that trade late January? Latest News and Media The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|
|||||||||||||||||||||
